Subtype
Cutaneous Melanoma of the Extremity
CI-CAN-00002483Explore in graph →
15 active trials5 evidence items
- NCIt
- C155305
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002483Explore in graph →
Variants & evidence
6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EMSY Amplification1 | ||||||||
| Talazoparib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID12148An 88-year-old male acral melanoma patient harbouring EMSY gene amplification without abnormal BRCA2 expression levels was treated with PARPi, talazoparib. The patient was treated with talazoparib at … (full text at CIViC) PMID 38778889 · Nassief et al., 2024 · Open in CIViC | civic |
| RAF1 Fusion1 | ||||||||
| Binimetinib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13148An 88-year-old patient with metastatic acral melanoma harboring a GOLGA4-RAF1 fusion received binimetinib 45 mg twice daily after progression on multiple immunotherapy regimens and clinical deteriorat… (full text at CIViC) PMID 39504576 · Khaddour et al., 2025 · Open in CIViC | civic |
| KIT rs170847331 | ||||||||
| (diagnostic) | Acral Lentiginous Melanoma | Diagnostic | B | Supports Positive | 3 | accepted | EID666The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most … (full text at CIViC) PMID 21119596 · Godshalk et al., 2011 · Open in CIViC | civic |
| NRAS G13R1 | ||||||||
| Belvarafenib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13214A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS Q61K1 | ||||||||
| Belvarafenib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13218A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| TERT Amplification1 | ||||||||
| (prognostic) | Acral Lentiginous Melanoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID514In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival. PMID 25219713 · Diaz et al., 2014 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.